Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.

British journal of cancer - 16 Jun 2009

Eklund C M, Tammela T L J, Schleutker J, Hurme M

Abstract excerpt

Growing evidence points to a role for inflammation in prostate carcinogenesis. The significance of C-reactive protein (CRP), an inflammatory and innate immunity molecule, has not been evaluated thoroughly in prostate cancer (PC). In this study of 739 Finnish patients with PC and 760 healthy men, we evaluated the associations of CRP genotypes and haplotypes with total PC risk and PC progression, using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Bone Neoplasms
Share to C-Reactive Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to Survival Rate

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 19436291
DOI: 10.1038/sj.bjc.6605081
PMCID: PMC2714238

Genes

CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.PMID 19436291Read ↗

C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.Semantic proximity Read ↗

Genetic variation across C-reactive protein and risk of prostate cancer.Semantic proximity Read ↗

Genetic factors regulating inflammation and DNA methylation associated with prostate cancer.Semantic proximity Read ↗

A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications.Semantic proximity Read ↗

TNF polymorphisms and prostate cancer risk.Semantic proximity Read ↗

Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.Semantic proximity Read ↗

Interleukins-6 -174G/C (rs1800795) and -572C/G (rs1800796) polymorphisms and prostate cancer risk.Semantic proximity Read ↗

Interleukin-6 promoter variants, prostate cancer risk, and survival.Semantic proximity Read ↗

Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia.Semantic proximity Read ↗

Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk.Semantic proximity Read ↗

Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: A population-based studySemantic proximity Read ↗

Association of elevated interleukin-33 serum levels with tumorstages in patients with prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.